Malignancies after kidney transplantation: 3 clinical case reports

详细信息    查看全文

• 作者：Egl? Dalinkevi?ien? (1132)
  Vytautas Kuzminskis (1132)
  Laura Kairevi?? (2132)
  Rasa Jan?iauskien? (2132)
  Daimantas Milonas (3132)
  Mindaugas Jievaltas (3132)
  Birut? Sribikien? (1132)
  Inga-Arūn? Bumblyt? (1132)
  
• 关键词：Kidney transplantation ; Malignancy ; Non ; Hodgkin’s lymphoma ; Kaposi’s sarcoma ; Germ cell testicular cancer (nonseminoma)
• 刊名：Central European Journal of Medicine
• 出版年：2013
• 出版时间：June 2013
• 年：2013
• 卷：8
• 期：3
• 页码：322-327
• 全文大小：787KB
• 参考文献：1. Sheil AG, Disney APS, Mathew TH, et al. De novo malignancy emerges as a major causes of morbidity and late failure in renal transplantation. Transplant Proc 1993;25:1383
  2. Peto J. Cancer epidemiology in the last century and the next decade. Nature 2001;411:390-95 CrossRef
  3. Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000;355:1886-887 CrossRef
  4. Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis 2002;39:E5 CrossRef
  5. Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression -de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007;71:1271-278 CrossRef
  6. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am. J. Transplant. 2004;4:905-13 CrossRef
  7. Morath C, Mueller M, Goldschmidt H et al. Malignancy in renal transplantation. J Am Soc Nephrol 2004;15:1582-588 CrossRef
  8. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for endstage renal disease: an international collaborative study. Lancet 1999;354:93-9 CrossRef
  9. Briggs JD. Causes of death after renal transplantation. Nephrol. Dial. Transplant. 2001;16:1545-54 CrossRef
  10. Yang TC, Shu KH, Cheng CH, Wu MJ, Lian JD. Malignancy following renal transplantation. Zhonghua Yi Xue Za Zhi (Taipei) 1998;61:281-88
  11. Howard RJ, Patton PR, Reed AI, et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002;73:1923-928 CrossRef
  12. Collins AJ, et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2003;42(5):S1–S230
  13. Miao Y, Everly JJ, Gross TG, Tevar AD et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009;87:1347-359 CrossRef
  14. Kauffman HM, Cherikh WS, McBride MA et al. Posttransplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 2006; 19:607-20 CrossRef
  15. Caillard S, Dharnidharka V, Agodoa L et al. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80:1233-243 CrossRef
  16. Liebowitz, D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998; 338:1413-421 CrossRef
  17. Opelz G, D?hler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222-30 CrossRef
  18. Dantal J, Hourmant M, Cantorovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporin regimens. Lancet 1998;351:623-28 CrossRef
  19. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619-625 CrossRef
  20. Schmidtko J, Wang R, Wu CL, et al. Posttransplant lymphoproliferative disorder associated with an Epstein-Barr-related virus in cynomolgus monkeys. Transplantation 2002;73:1431-439 CrossRef
  21. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-516 CrossRef
  22. Campistol JM, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006;1:581-89 CrossRef
  23. Kahan BD, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005;80:749-58 CrossRef
  24. Chapman JR, Capistol JM. Malignancy in renal transplantation: opportunities with proliferation signal inhibitors. Nephrol Dial Transplant 2007;22 (l):i1–i3 CrossRef
  25. Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new Mammalian target of rapamycin inhibitor. Transplantation. 2012;94(7):659-8 CrossRef
  26. Kasiske BL, Kukla A, Thomas D, et al. Lymphoproliferative Disorders After Adult Kidney Transplant: Epidemiology and Comparison of Registry Report With Claims-Based Diagnoses. Am J Kidney Dis 2011;58(6):971-80 CrossRef
  27. Gotti E, Remuzzi G: Post-transplant Kaposi’s sarcoma. J Am Soc Nephrol 1997;8:130-37
  28. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi’s sarcoma. Transplantation 2004;77:760-62 CrossRef
  29. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 2005;352:1317-323 CrossRef
  30. Shepherd FA, Maher E, Cardella C, et al. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol 1997;15:2371-377
  31. Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi’s sarcoma in the elderly: a randomized study of oral etoposide versus vinblastine. Cancer 1994;74:2873-878 CrossRef
  32. Olay Dahl, Geirfinn Vagstad, Bjarne Iversen. Cisplatin-based chemotherapy in a renal transplant recipient with metastatic germ cell testicular cancer. Acta Oncologica 1996; 35:759-61 CrossRef
  33. Dean C, Bloomfield D, Holt S. The challenge of germ cell tumour therapy in dialysis and transplantation. Nephrol Dial Transplant. 2005;20(12):2867-868 CrossRef
  34. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, et al. Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol. 2000;11:S1-6
  35. European Best Practice Guidelines. Nephrol Dial Transplant 2002;17(4):37
  36. Penn I. Transmission of cancer from organ donor. Nefrologia 1995;15(3):205-13
  37. Kauffman HM, McBride MA, Delmonico FL. First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation. 2000;70(12):1747-751 CrossRef
  38. Garrido G, Matesanz R. The Spanish National Transplant Organization (ONT) tumor registry. Transplantation 2008;85(8):S61-3 CrossRef
  
• 作者单位：Egl? Dalinkevi?ien? (1132)
  Vytautas Kuzminskis (1132)
  Laura Kairevi?? (2132)
  Rasa Jan?iauskien? (2132)
  Daimantas Milonas (3132)
  Mindaugas Jievaltas (3132)
  Birut? Sribikien? (1132)
  Inga-Arūn? Bumblyt? (1132)
  
  1132. Department of Nephrology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  2132. Department of Onco-haematology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  3132. Department of Urology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania
  

文摘

Post-transplant malignancies present an aggressive course and are a significant cause of morbidity and mortality. Tumours of viral ethiology have the greatest risk in renal transplant recipients. Oncogenic effect of immunosuppressive therapy is another major risk factor of post-transplant malignancy. We report cases of three different types of malignancies developed after kidney transplantation: non-Hodgkin’s lymphoma, Kaposi’s sarcoma and germ cell testicular cancer (nonseminoma).